NARB panel confirms recommendations to PatentHEALTH
This article was originally published in The Tan Sheet
Executive SummaryThe National Advertising Review Board agrees with earlier recommendations by the National Advertising Division that PatentHEALTH discontinue claims that Trigosamine Fast Acting joint health supplement "works" or "gets results" in three days. The claims in question were not supported by a randomized, double-blind, placebo-controlled study submitted by the Canton, Ohio-based firm, the Council of Better Business Bureaus panel reaffirms in a review of an appeal by PatentHEALTH. Additionally, the board sided with NAD that an advertorial for the product reasonably could be perceived by consumers to be a news story. Therefore, the panel recommended the firm discontinue any ads "not clearly and conspicuously identified as an advertisement." PatentHEALTH, which appealed NAD's decision last summer, says it will give "due consideration" to the panel's recommendations (1"The Tan Sheet" July 13, 2009)
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.